Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma

被引：2

作者：

Sharma, Sanjeev Kumar ^{[1
]}

Handoo, Anil ^{[1
]}

Choudhary, Dharma ^{[1
]}

Dhamija, Gaurav ^{[1
]}

Gupta, Nitin ^{[1
]}

机构：

[1] BLK Superspecial Hosp, Dept Hematooncol & Bone Marrow Transplant, New Delhi 110005, India

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2013年 / 19卷 / 05期

关键词：

Gastrointestinal mucositis; Chemotherapy; RISK-FACTORS;

D O I：

10.3748/wjg.v19.i5.784

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Mucositis is a known complication following use of chemotherapy, but fatal mucositis is unusual and management of such cases may be challenging. Pathologically there is denudation of mucosa of gastrointestinal tract. Severe cases can develop ileus and even perforation of bowel wall. We report here a case of multiple myeloma who developed World Health Organization grade 4 gut mucositis following the use of high dose melphalan with the expulsion of "intestine-like" material. (C) 2013 Baishideng. All rights reserved.

引用

页码：784 / 785

页数：2

共 50 条

[41] PROGNOSTIC FACTORS WITH HIGH-DOSE MELPHALAN FOR REFRACTORY MULTIPLE-MYELOMA
BARLOGIE, B
ALEXANIAN, R
SMALLWOOD, L
CHESON, B
DIXON, D
DICKE, K
CABANILLAS, F
BLOOD, 1988, 72 (06) : 2015 - 2019
[42] MULTIPLE-MYELOMA - COMPLETE REMISSION WITH HIGH-DOSE MELPHALAN CHEMOTHERAPY
RICHARDS, F
COLEMAN, M
COOPER, MR
BALLARD, WP
CANCER INVESTIGATION, 1985, 3 (01) : 15 - 21
[43] Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
Gillich, Cedric
Akhoundova, Dilara
Hayoz, Michael
Aebi, Yolanda
Largiader, Carlo R.
Seipel, Katja
Daskalakis, Michael
Bacher, Ulrike
Pabst, Thomas
CANCERS, 2023, 15 (10)
[44] Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
Gourzones, Claire
Bellanger, Celine
Lamure, Sylvain
Gadacha, Ouissem Karmous
De Paco, Elvira Garcia
Vincent, Laure
Cartron, Guillaume
Klein, Bernard
Moreaux, Jerome
CANCERS, 2019, 11 (04):
[45] Pharmacodynamics of High-Dose Melphalan in Myeloma
Nath, C. E.
Joshua, D.
Kerridge, I.
Kwan, Y. L.
Shaw, P. J.
Trotman, J.
Zeng, L.
Presgrave, P.
Tiley, C.
McLachlan, A.
Gurney, H.
Earl, J.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S34 - S35
[46] Palifermin reduces the incidence of oro-pharyngeal mucositis in multiple myeloma patients receiving high-dose melphalan with stem cell rescue
Guimaraes, P.
Coelho, P. S.
Melo, T.
Trigo, F.
Guimaraes, J. E.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 383 - 383
[47] Impact of oral mucositis on outcomes of multiple myeloma patients treated with high-dose melphalan conditioning and autologous stem cell transplantation (ASCT).
Jaguar, Graziella Chagas
Rodrigues, Gustavo Henrique
Guollo, Andre
Camandoni, Vanessa Oliveira
Magalhaes, Leila Maria
Melo, Pessoa
Alves, Fabio Abreu
Cordeiro Lima, Vladmir Claudio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[48] Dose dense dreifach* melphalan 100 for multiple myeloma
Berz, D.
McCormack, E.
Winer, E.
Karwan, P.
Colvin, G.
Rathore, R.
Lany, L.
Elfenbein, G.
Quesenberry, P.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 36 - 36
[49] INTERMITTENT HIGH-DOSE MELPHALAN PREDNISONE VS CONTINUOUS LOW-DOSE MELPHALAN TREATMENT IN MULTIPLE-MYELOMA
AHRE, A
BJORKHOLM, M
MELLSTEDT, H
HOLM, G
BRENNING, G
ENGSTEDT, L
GAHRTON, G
HALLEN, J
JOHANSSON, B
JOHANSSON, SGO
KARNSTROM, L
KILLANDER, A
LERNER, R
LOCKNER, D
LONNQVIST, B
SIMONSSON, B
STALFELT, AM
TERNSTEDT, B
WADMAN, B
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (04): : 499 - 506
[50] MODELING THROMBOCYTOPENIA AS A PREDICTOR OF OUTCOMES FOLLOWING SINGLE, HIGH DOSE MELPHALAN AND STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.
Irby, D.
Cottini, F.
Hade, E.
Hofmeister, C.
Phelps, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S120 - S120

← 1 2 3 4 5 →